REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Research/New Phase III Study Aims to Assess Tirzepatide’s Impact on Adolescent Obesity
Back to Research Library

New Phase III Study Aims to Assess Tirzepatide’s Impact on Adolescent Obesity

May 25, 2026
Share
Emerging Research

Based on emerging research. These findings are promising but require further validation.

About This Analysis

This article is an AI-assisted summary of a recently published news item or clinical trial listing. It is intended to provide a quick, accessible overview for the peptide research community. For full accuracy, always refer to the original source linked below.

New Phase III Study Aims to Assess Tirzepatide’s Impact on Adolescent Obesity

A new clinical trial has begun evaluating the effectiveness of tirzepatide, a promising peptide-based treatment, in managing obesity and related health issues among adolescents. The study, titled "SURMOUNT-ADOLESCENTS-2" (NCT06439277) and sponsored by Eli Lilly and Company, is currently recruiting participants for its Phase III stage.

Background

Adolescent obesity has become a significant public health concern worldwide, often leading to severe comorbidities such as cardiovascular diseases, type 2 diabetes, and mental health issues. Traditional weight management approaches like diet and exercise can be challenging for adolescents, who face unique physiological and environmental factors. The development of new therapeutic options like tirzepatide, a dual glucagon-like peptide-1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist, offers hope for more effective intervention strategies.

Tirzepatide has already shown promise in adult populations, with previous studies demonstrating significant reductions in body weight and improvements in cardiometabolic risk factors. However, its efficacy and safety in younger patients remain unexplored on a large scale until now. This new study aims to bridge this gap by assessing how tirzepatide interacts with lifestyle modifications like diet and exercise to combat obesity and associated conditions in adolescents.

Key Details

The "SURMOUNT-ADOLESCENTS-2" trial is set to enroll approximately 300 participants aged between 12 and 18 years who have been diagnosed with obesity and at least one weight-related comorbidity. The study will span around 76 weeks, during which participants will be randomly assigned either tirzepatide or a placebo while also receiving guidance on healthy nutrition and physical activity.

Researchers will closely monitor changes in bodyweight, cardiovascular risk factors (such as blood pressure, cholesterol levels), and other health indicators throughout the trial period. Additionally, safety assessments will include evaluating adverse events and conducting regular laboratory tests to ensure that tirzepatide remains safe for use in this younger demographic.

The primary objective is to determine whether adding tirzepatide to a regimen of healthy lifestyle habits can lead to clinically meaningful reductions in body weight and improvements in overall health outcomes compared to placebo. Secondary objectives include assessing long-term safety, adherence rates, and the impact on quality of life measures among participants.

Key Takeaways

  • Efficacy Evaluation: The study aims to determine if tirzepatide is effective in reducing obesity and improving cardiovascular risk factors when combined with lifestyle modifications.
  • Safety Monitoring: Comprehensive assessments will be conducted to ensure the safety profile of tirzepatide in adolescent populations over an extended period.
  • Comparative Analysis: Participants will receive either active treatment or placebo, allowing researchers to compare outcomes between groups accurately.
  • Comprehensive Follow-Up: Extensive monitoring throughout the study will provide valuable insights into long-term effects and patient experiences.

What This Means

For the peptide community, this trial represents a crucial step forward in understanding how advanced therapies like tirzepatide can be used effectively across different age groups. Given the growing prevalence of adolescent obesity and related health issues, such research is essential for developing targeted interventions that address these specific needs. If successful, the findings from "SURMOUNT-ADOLESCENTS-2" could pave the way for broader use of peptide-based treatments in pediatric settings, potentially transforming how we approach weight management and preventive care.

---

Source: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06439277) — Published 2026-05-19

This article is for informational purposes only and does not constitute medical advice.

Editor's Note

This analysis was generated using AI tools and reviewed by the Peptide Contacts editorial team. While we strive for accuracy, AI-generated content may contain errors or omissions. We encourage readers to review the original source for complete details, methodology, and data.

Peptide Contacts provides curated research summaries for informational purposes only. This content does not constitute medical advice. Always consult a qualified healthcare provider before making any health decisions.

Comments

Sign in to join the discussion

This article was generated using AI and may contain inaccuracies. It is provided for informational purposes only and does not constitute medical advice. Always verify information with the original source and consult a qualified healthcare provider before making any health decisions.